Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis - Takeaways - MDSpire

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis

  • By

  • Zepeng Li

  • Xiaoling Zhou

  • Lu Han

  • Meijie Shi

  • Huanming Xiao

  • Ming Lin

  • Xiaoling Chi

  • January 26, 2023

  • 0 min

Share

  • 1

    Cirrhosis is a leading cause of morbidity and mortality, with limited treatment options, especially in the decompensated stage.

  • 2

    Human umbilical cord blood-derived mesenchymal stem cells (HUCB-MSCs) offer a less invasive alternative for treating liver cirrhosis.

  • 3

    Prior studies indicate that HUCB-MSCs can improve liver function, but long-term efficacy and safety data are lacking.

  • 4

    This study evaluated the long-term outcomes of HUCB-MSC transplantation in patients with decompensated liver cirrhosis.

  • 5

    A total of 201 patients were enrolled, with 36 receiving HUCB-MSCT and 165 in a non-transplant group, matched for baseline characteristics.

Original Source(s)

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis

  • by Zepeng Li, Xiaoling Zhou, Lu Han, Meijie Shi, Huanming Xiao, Ming Lin, Xiaoling Chi

  • January 26, 2023

Related Content

The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss

Pediatric liver transplant at Mayo Clinic Children's

Mayo Clinic Children's delivers comprehensive care for children with liver disease, from early evaluation and second opinions to advanced therapies and pediatric liver transplantation.

  • April 2, 2026

  • 1 min
The immunometabolic nature of MASH: framing immune cells within metabolic dysfunction